Predicting the risk of cancer after unprovoked venous thromboembolism: external validation of the RIETE score.
J Thromb Haemost. 2017 Sep 06;:
Authors: Bertoletti L, Robin P, Jara-Palomare L, Tromeur C, Pastre J, Prevot-Bitot N, Mouneh T, Le Gal G, Salaun PY, MVTEP investigators
BACKGROUND: Most recent trials evaluating extensive screening strategies for occult cancer in patients with unprovoked venous thromboembolism failed, among other explanations because of an overall low rate of occult cancer. The RIETE investigators recently proposed a score aiming to identify a sub-group at higher risk.
METHODS: We retrospectively computed the RIETE score for all patients included in the MVTEP study, which evaluated the accuracy of FDG-PET in the screening of occult cancer in patients with unprovoked venous thromboembolism. Performance of the RIETE score was assessed by the proportion of patients classified in each risk group, and the corresponding rate of cancer diagnosis.
RESULTS: Among the 386 patients included in the analysis, 136 patients (35.3%) were classified as high risk by the RIETE score. Cancer was diagnosed in 16 (11.8%) of them, while it was diagnosed in 9 (3.6%) of the 250 patients with a low RIETE cancer score: odds ratio 3.6 (95% CI 1.53 to 8.32). The area under the ROC curve was 0.63 (95% CI 0.51 to 0.74).
CONCLUSION: the RIETE score seems to be able to identify a sub-group at high risk for cancer (10%), in our specific data-set of patients with unprovoked venous thromboembolism. This article is protected by copyright. All rights reserved.
PMID: 28875565 [PubMed - as supplied by publisher]